Azitra (AZTR) Receivables (2022 - 2026)

Azitra (AZTR) reported Receivables of $5108.0 for Q1 2026, up 460.09% quarter-over-quarter from $912.0 in Q4 2025.

Azitra (AZTR) Receivables (2022 - 2026) Analysis & Trends

Azitra has reported Receivables for 5 years, with the latest figure at $5108.0 in Q1 2026.

For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $5108.0; the trailing twelve-month figure through Mar 2026 stood at $5108.0 (changed N/A YoY), and the FY2025 full-year result was $912.0, up 291.42% from the prior year.
Receivables for Q1 2026 stood at $5108.0, up from $912.0 in the prior quarter.
The five-year high for Receivables was $885120.0 in Q2 2023, with the low at $233.0 in Q4 2024.
Historically, Receivables has averaged $236895.5 across 5 years, with a median of $92554.0 in 2023.
Annual changes were most pronounced in 2024 — Receivables tumbled 99.87% — and 2025, when it soared 291.42%.
Azitra's Receivables stood at $350000.0 in 2022, then sank by 48.57% to $180000.0 in 2023, then tumbled by 99.87% to $233.0 in 2024, then soared by 291.42% to $912.0 in 2025, then surged by 460.09% to $5108.0 in 2026.
The last three Receivables figures came in at $5108.0 (Q1 2026), $912.0 (Q4 2025), and $233.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Azitra	20,900.00	20,900.00	-	5,108.00

Download Data